000 02165nam a22001817a 4500
003 OSt
005 20160506120752.0
008 160401b xxu||||| |||| 00| 0 eng d
040 _cNational Acoustic Laboratories
100 _aEnglish, Ruth
245 _aFitting recommendations and clinical benefit associated with use of the NAL-NL2 hearing aid prescription in Nucleus cochlear implant recipients
520 3 _aObjective: For a group of cochlear implant recipients, who use hearing aids in the contralateral ear, the benefit of NAL-NL2 relative to a recipients’ own prescription was assessed. Whether there was a preferred frequency response and/or gain deviation from NAL-NL2 was then investigated. Design: Speech recognition and self-reported ratings of benefit were examined for the recipients’ own prescription compared to the NAL-NL2 prescription, in the bimodal and hearing-aid alone conditions. Paired-comparison of hearing-aid frequency response was conducted with default NAL-NL2 and two variants, a low frequency boost or cut. Using a loudness balancing procedure, the hearing-aid gain required to achieve equal loudness between the devices was measured. Study sample: Sixteen adults with post-lingual hearing loss. Results: A 22% increase in group median word score in quiet with use of NAL-NL2 in the hearing-aid alone condition. In the bimodal condition there was no improvement with NAL-NL2. Default NAL-NL2 frequency response was preferred by 67% of participants. For 56% of participants, the preferred gain to achieve loudness balance across bimodal devices was within 5-dB of prescribed values. Conclusions: The NAL-NL2 prescription provides a high level of clinical performance, and an acceptable frequency response and gain for most participants.
650 _aCochlear implant; bimodal; acoustic hearing; hearing-aid prescription
700 _aKerrie Plant ...[et.al.]
773 0 _g2016; Early Online: 1–6
_tInternational Journal of Audiology
856 _uhttp://dspace.nal.gov.au/xmlui/bitstream/handle/123456789/346/Fitting%20recommendations%20and%20clinical%20benefit.pdf?sequence=1&isAllowed=y
942 _2udc
_cARTICLE
999 _c2537
_d2537